Vertex Pharmaceuticals, Inc. (VRTX)

bhessel (97.85) Submitted: 12/24/07 9:25 AM : Start Price: $31.51 VRTX Score: 23.59

17 Apr 07

Vertex Pharmaceuticals is a biotech company with a protease inhibitor drug—telaprevir—just completing Phase II testing that promises dramatic improvement in the treatment of Type 1 hepatitis C ( http://en.wikipedia.org/wiki/Hepatitis_c ), ...

Report this Post Replies: 7 | Reply | Permalink

Hukphinn (99.22) Submitted: 7/14/06 9:10 PM : Start Price: $32.87 VRTX Score: 5.05

VX-950 for HCV has tremendous promise. Share price will probably see a fair amount of volatility, so I'd accumulate on substantial dips and hold for the long-term.

Report this Post Replies: 0 | Reply | Permalink

fogman24 (99.87) Submitted: 7/20/07 5:24 PM : Start Price: $28.41 VRTX Score: 33.41

Blockbuster potenial drug that could be launched as early as 2010. Seems on track with phase 3 clinical trials coming up in the next couple of quarters. So far has shown great results. Would be first to market with the advantage of having the mark...

Report this Post Replies: 0 | Reply | Permalink

StarbellySneech (23.40) Submitted: 3/28/07 3:42 PM : Start Price: $27.89 VRTX Score: 34.69

I have owned Vertex Pharmaceuticals for a while now and I am happy with my returns. But now the price has dropped so low that I just bought more, and why not add to CAPS? The main revenue driver should be telaprevir for hepatits C virus. I know it...

Report this Post Replies: 1 | Reply | Permalink

genedom (97.87) Submitted: 9/27/07 2:45 AM : Start Price: $37.99 VRTX Score: -8.10

A 5-billion dollar company with the drug approval two years away is too pricey for me. Not mention anything can happen in phase III trial.

Report this Post Replies: 0 | Reply | Permalink

mansloth (96.97) Submitted: 8/21/06 3:23 AM : Start Price: $32.42 VRTX Score: 9.17

Seems to have the pipeline, the partnerships, and the cash to grow into a much larger company.

Price seems a bit rich now, and in fact I wouldn't be surprized to see the stock dip some in the coming year. However, as time goes by and the products...

Report this Post Replies: 0 | Reply | Permalink

TMFBreakerCharly (29.87) Submitted: 4/26/06 9:04 PM : Start Price: $33.85 VRTX Score: 5.50

stock is down 10% this morning. While $33 isn't the best buy price (try for under $30) this is a huge long-term winner because of its hepatitis C drug VX-950.

Report this Post Replies: 4 | Reply | Permalink

NetscribeBiotech (76.22) Submitted: 5/30/07 7:01 AM : Start Price: $30.44 VRTX Score: -29.95

Getting oneself established firmly in the pharmaceutical market on the back of a strong product portfolio is a lengthy and expensive procedure. It gets even tougher when the playing field is comprised of giants like GlaxoSmithKline, Roche, and Novart...

Report this Post Replies: 0 | Reply | Permalink

Unklesam101 (28.68) Submitted: 5/31/06 6:11 PM : Start Price: $33.81 VRTX Score: 2.64

I have owned this Co for 6 years. I believe in another 6 it could be well North of current valuation. Its HCV compound is so far "Best in Class."-

Report this Post Replies: 1 | Reply | Permalink

Ganndalf (< 20) Submitted: 2/13/07 9:40 PM : Start Price: $31.36 VRTX Score: 22.74

Let me be perfectly honest...

I have been rummaging in Databasebob's very full closet of stocks, and all the way down at the bottom of the heap way in the back I dug up this little gem. I hope he doesn't miind if I just borrow it for a little while...

Report this Post Replies: 1 | Reply | Permalink